CEBP：不同乳腺癌亚型之间的差异性或帮助新型疗法的开发

2015-10-15 佚名生物谷

少数民族女性，尤其是非洲裔美国人、西班牙白人和美洲印第安人，往往容易被诊断为恶性乳腺癌，而这些患者不太可能接受推荐的方案进行治疗，因此其更容易因乳腺癌而死亡；此前研究中研究人员阐明了不同阶段疾病及患者死亡率之间的不一致性，但并没有对疾病的亚型进行分析对比。刊登在国际杂志Cancer Epidemiology，Biomarkers & Prevention的一项研究论文中，来自西雅图Fr

少数民族女性，尤其是非洲裔美国人、西班牙白人和美洲印第安人，往往容易被诊断为恶性乳腺癌，而这些患者不太可能接受推荐的方案进行治疗，因此其更容易因乳腺癌而死亡；此前研究中研究人员阐明了不同阶段疾病及患者死亡率之间的不一致性，但并没有对疾病的亚型进行分析对比。

刊登在国际杂志Cancer Epidemiology，Biomarkers & Prevention的一项研究论文中，来自西雅图Fred Hutchinson 癌症研究中心的科学家就对此进行了研究，他们收集了18个来自美国国家癌症研究所中监测，流行病学和最终结果（SEER）程序的基于人口癌症登记处提供的数据，这些数据包括了102，064名女性的：人口学特征、阶段、肿瘤级别、大小、原始疗法、健康保险情况、肿瘤亚型、激素受体状态、人表皮生长因子受体2-neu的状态。

研究者发现，相比非洲裔美国女性而言，非西班牙裔的白人女性更易于患较小尺寸的肿瘤，而且更易于患较低侵袭性的HR+/HER2-类型的乳腺癌，而非洲裔美国女性更易于患较大尺寸的肿瘤以及恶性的三阴性乳腺癌。与此同时研究者还发现，在所有的乳腺癌类型中，对于一些种族和族裔群体而言，较晚的诊断和不接受标准疗法进行治疗之间存在一种固定的模式。

近些年来，增加乳腺癌分子和遗传特性的信息可以明显帮助改善治疗疾病的疗法，当前乳腺癌的治疗方法依赖于乳腺癌的不同类型，即取决于雌激素受体、孕酮受体和HER2的状态，这就是为何研究者认为考虑不同乳腺癌亚型的不一致性对于研究的重要性了。

研究者Chen说道，一旦给定种族和民族的差异性，和乳腺癌相关的适合的靶向干预措施就会有效地帮助减少不同癌症亚型之间的差异并且增加患者的生存率。最后研究者表示，本文研究对于后期我们收集更多的研究数据，并且基于相关的研究数据开发更多治疗乳腺癌的新型疗法提供希望。

原文出处：

Lu Chen1，and Christopher I.Li，Racial Disparities in Breast Cancer Diagnosis and Treatment by Hormone Receptor and HER2 Status.CEBP.2015

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=95621, encodeId=f9a895621cb, content=学习啦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:54:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40408, encodeId=0a1a4040856, content=学了啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Fri Oct 23 12:35:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924859, encodeId=debd192485984, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Oct 27 04:06:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38923, encodeId=b9453892315, content=学习！, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Thu Oct 15 13:14:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
2016-08-03 1dd8c52fm63(暂无匿称)

学习啦！

113 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=95621, encodeId=f9a895621cb, content=学习啦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:54:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40408, encodeId=0a1a4040856, content=学了啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Fri Oct 23 12:35:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924859, encodeId=debd192485984, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Oct 27 04:06:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38923, encodeId=b9453892315, content=学习！, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Thu Oct 15 13:14:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
2015-10-23 slicer

学了啦

161 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=95621, encodeId=f9a895621cb, content=学习啦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:54:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40408, encodeId=0a1a4040856, content=学了啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Fri Oct 23 12:35:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924859, encodeId=debd192485984, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Oct 27 04:06:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38923, encodeId=b9453892315, content=学习！, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Thu Oct 15 13:14:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
2015-10-27 smartjoy

#新型疗法#

94 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=95621, encodeId=f9a895621cb, content=学习啦！, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 03 05:54:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40408, encodeId=0a1a4040856, content=学了啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ba41656652, createdName=slicer, createdTime=Fri Oct 23 12:35:00 CST 2015, time=2015-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924859, encodeId=debd192485984, content=<a href='/topic/show?id=7d1558259f5' target=_blank style='color:#2F92EE;'>#新型疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58259, encryptionId=7d1558259f5, topicName=新型疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Tue Oct 27 04:06:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=38923, encodeId=b9453892315, content=学习！, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21de1652194, createdName=1ddcd6e4m96(暂无匿称), createdTime=Thu Oct 15 13:14:00 CST 2015, time=2015-10-15, status=1, ipAttribution=)]
2015-10-15 1ddcd6e4m96(暂无匿称)

学习！

164 0 举报

期刊

CANCER EPIDEM BIOMAR 进入期刊论坛 GetPortalImpactFactorByIdResponse(projectId=1, id=d85c1314, cover=https://img.medsci.cn/images/journal/cover/2021/qQQ_202109271314375700.jpg, fullname=CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, abbr=CANCER EPIDEM BIOMAR, pyear=1991, frequence=Monthly, articleNumbers=5641, citedSelf2015=3.8, acceptanceRate=40.0, submissionToAcceptance=1.67, averageReviewTime=平均1.67月, reviewFee=null, pageFee=null, publishedRatio=2023年中国人文章占该期刊总数量1.01% (2022年为1.55%), issn=1055-9965, greenSci=https://www.greensci.net/search?kw=1055-9965, scijournal=https://www.scijournal.org/impact-factor-of-CANCER-EPIDEM-BIOMAR.shtml, medsciHotlightString=null, medsciHotlightRealtime=6.653, medsciHotlight=9.91, medsciHotlight5year=9.53799, citescore=0.0, hIndex=192, impactFactor=3.8, orgnization=American Association for Cancer Research Inc., orgnizationUrl=http://www.aacr.org/, country=United States, countryCn=美国, isOa=0, isOaString=否, sciScie=Science Citation Index|Science Citation Index Expanded|Current Contents - Clinical Medicine|Current Contents - Life Sciences|BIOSIS Previews, bigclassCas=医学 2区, smallclassCas=医学 2 区, website=http://cebp.aacrjournals.org/, websiteHits=13958, guideForAuthor=null, guideForAuthorHits=22, submitWebsite=https://cebp.msubmit.net/cgi-bin/main.plex, submitWebsiteHits=4228, content=Cancer Epidemiology, Biomarkers & Prevention publishes original, peer-reviewed research on cancer causation, mechanisms of carcinogenesis, prevention, and survivorship. Topics include descriptive, analytical, biochemical, and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention., totalCites=21437, brief=CANCER EPIDEM BIOMAR杂志医学行业，“<strong><a target="_blank" href="/sci/index.do?smallclass=公共卫生、环境卫生与职业卫生" >公共卫生、环境卫生与职业卫生</a></strong>”子行业的优秀级杂志, articleType=绝大部分收录论著，也接收少量其它类型文章, medsciHeat=黑红, medsciComment=CANCER EPIDEM BIOMAR在该细分领域可能是一流杂志，可能是创刊时间短或不是热门学科，整体来说，国内学者关注度仍然不够。对于投稿而言，建议多向"&abbr&"投稿，当然期刊也应该加强品牌宣传。, medsciExplanation=MedSci期刊指数是根据中国科研工作者（含医学临床，基础，生物，化学等学科）对SCI杂志的认知度，熟悉程度，以及投稿的量等众多指标综合评定而成。当然，具体的，您还可以结合“<a href='https://www.medsci.cn/sci/submit.do?id=d85c1314'>投稿经验系统</a>”，进行综合判断，这更是大家的实战经验，值得分享和参考。<br> 注意，上述MedSci期刊指数采用MedSci专利技术，由计算机系统自动计算，并给出建议，存在不准确的可能，仅供您投稿选择杂志时参考。, tags=[ImpactFactorTagDto(id=119, tagName=肿瘤, createdHits=7), ImpactFactorTagDto(id=41293, tagName=肿瘤与基因多态性关联分析, createdHits=1), ImpactFactorTagDto(id=3225, tagName=表观遗传学, createdHits=1), ImpactFactorTagDto(id=23304, tagName=分子标记物, createdHits=1), ImpactFactorTagDto(id=15381, tagName=肿瘤标志物, createdHits=1)], citeScoreList=[GetImpactFactorCiteScoreListResponse(year=2016, citescore=3.95), GetImpactFactorCiteScoreListResponse(year=2017, citescore=4.09), GetImpactFactorCiteScoreListResponse(year=2018, citescore=4.51), GetImpactFactorCiteScoreListResponse(year=2019, citescore=8.2), GetImpactFactorCiteScoreListResponse(year=2020, citescore=0.0)], medsciIndexList=[GetImpactFactorMedsciIndexListResponse(year=2021, medsciHotlight=10.593), GetImpactFactorMedsciIndexListResponse(year=2022, medsciHotlight=10.734), GetImpactFactorMedsciIndexListResponse(year=2023, medsciHotlight=10.125), GetImpactFactorMedsciIndexListResponse(year=2024, medsciHotlight=7.383), GetImpactFactorMedsciIndexListResponse(year=2025, medsciHotlight=6.653)], citeScoreGradeList=[GetImpactFactorCiteScoreGradeResponse(smallClass=Medicine - Epidemiology , rank=12/89), GetImpactFactorCiteScoreGradeResponse(smallClass=Medicine - Oncology , rank=50/321)], pmcUrl=https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1055-9965[ISSN], pubmedUrl=https://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION[ta], article_number=580, article_number_cn=9, isJournalMember=null, journalType=sci)

投稿信息杂志简介 MedSci指数

杂志官网投稿链接作者需知

中国SCI论文 Pubmed全文检索

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CEBP：不同乳腺癌亚型之间的差异性或帮助新型疗法的开发

相关资讯

科室

工具

服务

肿瘤科

CEBP：不同乳腺癌亚型之间的差异性 或帮助新型疗法的开发

相关资讯

科室

工具

服务

CEBP：不同乳腺癌亚型之间的差异性或帮助新型疗法的开发